stoxline Quote Chart Rank Option Currency Glossary
  
Exicure, Inc. (XCUR)
10.09  0.08 (0.8%)    02-13 16:00
Open: 10.25
High: 10.25
Volume: 12,600
  
Pre. Close: 10.01
Low: 9.9474
Market Cap: 26(M)
Technical analysis
2025-02-13 4:52:26 PM
Short term     
Mid term     
Targets 6-month :  14.44 1-year :  17.81
Resists First :  12.36 Second :  15.25
Pivot price 10.8
Supports First :  7.69 Second :  6.4
MAs MA(5) :  10.16 MA(20) :  10.86
MA(100) :  9.86 MA(250) :  5.39
MACD MACD :  -0.8 Signal :  -0.8
%K %D K(14,3) :  2.9 D(3) :  5
RSI RSI(14): 44.4
52-week High :  36 Low :  1.44
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ XCUR ] has closed above bottom band by 21.5%. Bollinger Bands are 74.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.26 - 10.33 10.33 - 10.39
Low: 9.81 - 9.89 9.89 - 9.95
Close: 9.99 - 10.11 10.11 - 10.2
Company Description

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Headline News

Wed, 22 Jan 2025
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Yahoo Finance

Wed, 22 Jan 2025
Exicure Acquires GPCR Therapeutics USA, Signs Major Licensing Deal for Drug Development - StockTitan

Fri, 27 Dec 2024
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha

Sat, 21 Dec 2024
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes - Business Wire

Wed, 27 Nov 2024
Exicure Stock Soars to 52-Week High, Hits $32.75 - Investing.com

Wed, 20 Nov 2024
Exicure stock soars to 52-week high, hits $6.91 - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 771190 (%)
Held by Institutions 46.7 (%)
Shares Short 56 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5.8e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 193.1 %
Return on Equity (ttm) -26.5 %
Qtrly Rev. Growth 500000 %
Gross Profit (p.s.) 0
Sales Per Share -112.83
EBITDA (p.s.) 390625
Qtrly Earnings Growth -2.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.09
Price to Cash Flow 7.38
Stock Dividends
Dividend 0
Forward Dividend 31090
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android